X
[{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Third Pole Therapeutics Announces First Patient Dosed in Feasibility Study with eNOfit\u2122 Portable Inhaled Nitric Oxide Delivery System","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Third Pole Therapeutics
Filters
Companies By Therapeutic Area
Details:
eNOfit is a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).
Lead Product(s):
Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: eNOfit
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 11, 2023
Details:
Third Pole's technology generates pure inhaled nitric oxide (iNO) for therapeutic use and delivers it to the patient on demand, providing clinicians with greater flexibility than with iNO therapeutics stored in compressed gas cylinders.
Lead Product(s):
Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $32.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
December 14, 2022